{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"6.6","value":"5.6"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"7.6","value":"5.5"},{"groupId":"OG002","lowerLimit":"3.6","upperLimit":"9.7","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first. Per planned analysis, PFS by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"},{"description":"Overall 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. Of these 68 participants, 54 were confirmed as HR+/HER2-, had progressed on at least one prior hormonal therapy in the metastatic setting, and had received at least one dose of 10 mg/kg SG. These 54 participants were included in the analysis of safety and were referred to as the HR+/HER2- mBC Population.","id":"OG001","title":"HR+/HER2- mBC Population"},{"description":"Overall 49 participants with metastatic urothelial cancer were enrolled in the study and received at least one dose of SG. Of these 49 participants, 45 had either relapsed after or were refractory to at least one prior standard therapeutic regimen and received at least one dose of 10 mg/kg SG. These 45 participants were included in the analysis of safety and were referred to as the mUC Population.","id":"OG002","title":"mUC Population"}],"paramType":"MEDIAN","populationDescription":"* Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease \\& who received at least 1 dose of 10 mg/kg SG\n* HR+/HER2-mBC: Participants with HR+/HER2- mBC who progressed on at least 1 prior hormonal therapy \\& who received at least 1 dose of 10 mg/kg SG\n* mUC: Participants who had relapsed after or were refractory to at least 1 prior treatments \\& who received at least 1 dose of 10 mg/kg SG","reportingStatus":"POSTED","timeFrame":"Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)","title":"Progression Free Survival (PFS) by Local Assessment","type":"SECONDARY","unitOfMeasure":"months"}